Título Abreviado: ECM 18/1445 – PERSEUS
Investigador Principal: María Victoria Mateos Manteca
Código EUDRACT: 2018-002992-16
Código Identificativo: ECI2019/0100

EMN17/54767414MMY3014

A Phase III Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects With Previously Untreated Multiple Myeloma Who Are Eligible for High-dose Therapy

Estado: ACTIVO

Pin It en Pinterest